Korean J Hematol.  2006 Sep;41(3):215-219. 10.5045/kjh.2006.41.3.215.

A Case of Mantle Cell Lymphoma Treated with Autologous Stem Cell Transplantation and Rituximab

  • 1Department of Internal Medicine, Pochon CHA University College of Medicine, Seongnam, Korea. sychong@cha.ac.kr
  • 2Department of Radiation Oncology, Pochon CHA University College of Medicine, Seongnam, Korea.


Mantle cell lymphoma is a subtype of aggressive non-Hodgkin's lymphoma and usually presents in advanced stages. When treated with a regimen such as CHOP, the median survival is about three years. More aggressive front-line therapy with the hyper-CVAD regimen or high-dose therapy with stem cell support has shown encouraging results in several trials. The addition of rituximab to the chemotherapy regimens, or high-dose therapy, increased the response and survival rates in patients with mantle cell lymphoma. We report a case of mantle cell lymphoma that was successfully treated with aggressive front-line treatment strategies. The patient achieved complete remission with initial hyper-CVAD regimen, and was consolidated with autologous stem cell transplantation and subsequent rituximab.


Mantle cell lymphoma; Hyper-CVAD; Rituximab; Autologous stem cell transplantation
Full Text Links
  • KJH
export Copy
  • Twitter
  • Facebook
Similar articles
Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr